This antibody recognizes the N-teminus of CD195, an approximately 45 kDa G-protein coupled receptor 1 family protein expressed on resting T cells, monocytes, macrophages, and immature dendritic cells.

Anwendungen

Flow Cytometry, IP, WB, ICC, ELISA

Verdünnungen

WB: Do not boil cell lysates prior to SDS-PAGE, Flow Cytometry: 1-4 µg/ml.

Reaktivität

Human

Immunogen

CCR5 peptide (Met1-Lys22) KLH conjugate.

Wirt

Mouse

Klonalität

Monoclonal

Klon

T21/8

Isotyp

IgG1

Leichte Ketten

kappa

Konjugat

Unconjugated

Reinigung

Protein A chromatography.

Konzentration

1 mg/ml

Geschätztes MW

45 kDa

Produktform

Liquid

Formulierung

Supplied in Phosphate Buffered Saline, pH 7.4, with 15 mM Sodium Azide.

Lagerung

Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze/thaw cycles.

Synonyme

AM4 7, C C chemokine receptor type 5, C C CKR 5, C-C chemokine receptor type 5, C-C CKR-5, C-C motif chemokine receptor 5 A159A, CC Chemokine Receptor 5, CC Chemokine Receptor Type 5, CC CKR 5, CC-CKR-5, CCCKR 5, CCCKR5, CCR 5, CCR-5, CCR5 chemokine (C C motif) receptor 5, CCR5_HUMAN, CD 195, CD195, CD195 Antigen, Chemokine C C motif receptor 5, Chemokine receptor CCR5, CHEMR13, CKR 5, CKR5, CMKBR 5, CMKBR5, FLJ78003, HIV 1 Fusion Coreceptor, HIV-1 fusion coreceptor, HIV1 fusion coreceptor, IDDM22, MIP-1 alpha receptor

Isotyp-Kontrollantikörper

Kompatible Sekundärantikörper

Haftungsausschluss

Dieses Produkt ist nur für Forschungszwecke bestimmt. Es ist nicht für diagnostische oder therapeutische Zwecke bestimmt.

Produktreferenzen für diesen Klon (1)

Bild Vergrößern

Loss of Fas expression and high expression of HLA-E promoting the immune escape of early colorectal cancer cells

Verweise: Anti-CCR5 Antibody [T21/8] (ab110103)

Abstrakt:

Previous studies have investigated the mechanisms of immune evasion of tumor cells in numerous types of advanced solid malignant tumor, and several types of immune preparations have been administered as antitumor adjuvant therapies. However, in the majority of studies, the efficacy of therapies has been revealed to be limited. The present study aimed to investigate the immune evasion mechanisms employed by early colorectal cancer cells and the expression of the molecules associated with immune evasion during the malignant transformation process of normal colorectal epithelial cells to measure the effects of immune intervention for early colorectal cancer, and to improve the efficacy of immunotherapy. A total of 60 colorectal tissues, including 15 normal mucosa, 15 adenoma, 15 early cancer and 15 advanced cancer tissues, from patients undergoing endoscopic procedures in Huadong Hospital Affiliated to Fudan University (Shanghai, China) were collected. A comparison of baseline characteristics among these four groups was performed. The expression levels of human leukocyte antigen-A (HLA-A), apoptosis antigen 1 (Fas), c-c chemokine receptor type 5 (CCR5), Fas ligand (FasL) and HLA-E in each group were detected by immunohistochemical analysis. Furthermore, 15 patients with advanced colorectal cancer were enrolled into the present study. Advanced cancer and paracancer tissues (normal mucosal tissues 3 cm away from the margin of cancer tissues) were collected from each patient by colonoscopic biopsy. The expression levels of HLA-A, Fas, CCR5, FasL and HLA-E in each group were detected by western blot analysis. During the malignant transformation process of normal colorectal epithelial cells, the expression levels of CCR5, FasL and HLA-E increased significantly (P<0.001), whilst the expression levels of Fas reduced significantly (P=0.0271). In the early cancer group, the expression levels of Fas reduced significantly (P=0.0239), whilst the expression levels of HLA-E increased significantly (P<0.001) compared with adenoma group. In conclusion, a loss of Fas expression and high expression levels of HLA-E may promote the immune evasion of early colorectal cancer cells.

Publikation anzeigen